Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Subcutaneous Tocilizumab in Monotherapy or in Combination With csDMARD in Patients With Moderate to Severe Active Rheumatoid Arthritis and Followed by Hospital and Office Based Rheumatologists: Non Interventional Study to Describe Real-World Drug Retention Rate of the Biotherapy at 1 Year

NCT02608112 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02608112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02608112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Subcutaneous Tocilizumab in Monotherapy or in Combination With csDMARD in Patients With Moderate to Severe Active Rheumatoid Arthritis and Followed by Hospital and Office Based Rheumatologists: Non Interventional Study to Describe Real-World Drug Retention Rate of the Biotherapy at 1 Year
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
December 31, 2015
Completion date
July 26, 2018
Enrollment
291 (estimated)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis